title: Sirolimus- versus paclitaxel-eluting stent implantation for unprotected left main coronary artery stenosis.
abstract: We performed this study in order to compare the immediate and mid-term outcomes of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in lesions of the unprotected left main coronary artery (LMCA). We assessed 54 patients from 5 centers who had undergone unprotected LMCA stenting (35 SES and 19 PES). The procedural success rates were 100 and 95%, respectively, in the SES and PES patients (p = 0.19). At the 6-month clinical follow-up, the event-free probability was 100% in the SES group, and 88% in the PES group (p = 0.07). At the 6-month angiographic follow-up (n = 24), the SES group exhibited a slightly lower late loss than did the PES group (0.24 +/- 0.44 vs. 0.65 +/- 0.60 mm, p = 0.09), and the restenosis rates were 8 and 9% (p = 0.94) in the SES and PES patients, respectively. In conclusion, both groups exhibited excellent in-hospital and 6-month outcomes with no significant differences between them.
authors.affiliation: Kangnam Sacred Heart Hospital, Seoul, Republic of Korea.
authors.forename: Sang Hak
authors.initials: SH
authors.lastname: Lee
authors.forename: Young-Guk
authors.initials: YG
authors.lastname: Ko
authors.forename: Yangsoo
authors.initials: Y
authors.lastname: Jang
authors.forename: Hyuck Moon
authors.initials: HM
authors.lastname: Kwon
authors.forename: Seung-Hwan
authors.initials: SH
authors.lastname: Lee
authors.forename: Jung Han
authors.initials: JH
authors.lastname: Yoon
authors.forename: Si Hoon
authors.initials: SH
authors.lastname: Park
authors.forename: Byung Ok
authors.initials: BO
authors.lastname: Kim
authors.forename: Dong Woon
authors.initials: DW
authors.lastname: Jeon
authors.forename: Joo Young
authors.initials: JY
authors.lastname: Yang
authors.forename: Seung-Ki
authors.initials: SK
authors.lastname: Ryu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D019917:Blood Vessel Prosthesis Implantation; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000209:etiology; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000628:therapy
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus